We are live on ! Find out more
Deerfield Management

Deerfield Management Portfolio holdings

AUM $6.47B Turnover 21.35%
1-Year Est. Return 71.25%
 

Deerfield Management is an investment firm dedicated to healthcare, backing therapeutics, medical device, diagnostics and digital health companies at every stage, from startups to mature public businesses. Arnold Snider, a former Tiger Management managing director and Kidder Peabody pharmaceutical analyst, founded the firm in 1994 and retired in 2005. James Flynn joined in 2000 and later became chief executive. Its first healthcare innovations fund, raised in 2015, aimed at scientific advances that could lead to new treatments for genetic diseases, cancer and orphan diseases. In 2020 Deerfield took over Melinta Therapeutics, swapping secured debt for all of its equity after Melinta filed for bankruptcy. Its in-house research arm, Deerfield Discovery and Development, moves early-stage therapies from scientific discovery into the clinic.

This Fund
S&P 500
This Quarter Est. Return
+15.28%
1 Year Est. Return
+71.25%
3 Year Est. Return
+262.82%
5 Year Est. Return
+342.14%
10 Year Est. Return
+1,890.99%
AUM
$2.15B
AUM Growth
-$394M
Cap. Flow
-$894M
Cap. Flow %
-41.57%
Top 10 Hldgs %
42.88%
Holding
116
New
14
Increased
12
Reduced
29
Closed
26
Avg Time Held
1.2 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
0.9 years

Sector Composition

Rank Sector Weight
1 Healthcare 79.82%
2 Miscellaneous 16.84%
3 Financials 3.34%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
GWPH
1
DELISTED
GW Pharmaceuticals
GWPH
$134M 6.23%
1,008,475
+16,675
+2% +$1.59M
2015 Q1
6 quarters
PTLA
2
DELISTED
Portola Pharmaceuticals
PTLA
$128M 5.96%
5,639,727
+1,966,000
+54% +$46.1M
2013 Q2
13 quarters
HZNP
3
DELISTED
Horizon Therapeutics
HZNP
$117M 5.43%
6,434,439
-7,305,822
-53% -$143M
2013 Q4
11 quarters
NXTM
4
DELISTED
NxStage Medical
NXTM
$102M 4.76%
4,099,175
-406,293
-9% -$9.47M
2013 Q2
13 quarters
AVXS
5
DELISTED
AveXis
AVXS
$92.2M 4.29%
2,236,701
– –
2016 Q1
2 quarters
ADPT icon
6
DELISTED
Adeptus Health Inc
ADPT
$68.9M 3.21%
1,600,861
– –
2014 Q3
8 quarters
DBVT icon
7
DBV Technologies
DBVT
$567M
$63.3M 2.95%
174,323
– –
2014 Q4
7 quarters
VNDA icon
8
Vanda Pharmaceuticals
VNDA
$208M
$57.2M 2.66%
3,435,576
-2,561,115
-43% -$34.5M
2013 Q3
12 quarters
NVRO icon
9
DELISTED
Nevro
NVRO
$56M 2.6%
+536,355
New +$48.4M
2016 Q3
0 quarters
VTRS icon
10
Viatris
VTRS
$22.5B
$54.3M 2.52%
1,423,334
+84,000
+6% +$3.73M
2015 Q1
6 quarters
XNCR icon
11
Xencor
XNCR
$2.5B
$54.1M 2.52%
2,210,900
-719,586
-25% -$15.2M
2015 Q1
6 quarters
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
$50.5M 2.35%
1,338,829
-1,181,756
-47% -$26.1M
2013 Q4
11 quarters
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$50.5M 2.35%
4,072,809
– –
2013 Q2
13 quarters
AET
14
DELISTED
Aetna Inc
AET
$42.3M 1.97%
366,000
– –
2015 Q1
6 quarters
AAC
15
DELISTED
AAC Holdings
AAC
$38.1M 1.77%
2,189,849
+40,147
+2% +$791K
2015 Q1
6 quarters
UAM
16
DELISTED
Universal American
UAM
$35.1M 1.63%
4,592,060
+269,060
+6% +$1.99M
2013 Q2
13 quarters
ALPN icon
17
DELISTED
Alpine Immune Sciences Inc
ALPN
$30.3M 1.41%
933,103
– –
2015 Q2
5 quarters
EHTH icon
18
eHealth
EHTH
$11.3M
$29.6M 1.38%
2,640,609
– –
2014 Q1
10 quarters
WBA icon
19
DELISTED
Walgreens Boots Alliance
WBA
$28.7M 1.33%
355,957
-255,500
-42% -$20.8M
2015 Q1
6 quarters
HUM icon
20
Humana
HUM
$46.8B
$28.2M 1.31%
159,500
– –
2016 Q2
1 quarter
LKFT icon
21
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.18B
$27.4M 1.27%
423,112
-35,000
-8% -$1.97M
2015 Q2
5 quarters
SYRS icon
22
DELISTED
Syros Pharmaceuticals
SYRS
$25.1M 1.17%
181,278
-28,244
-13% -$3.58M
2016 Q2
1 quarter
BOLD icon
23
DELISTED
Audentes Therapeutics
BOLD
$25M 1.16%
+1,403,653
New +$21.3M
2016 Q3
0 quarters
TSRO
24
DELISTED
Tesaro
TSRO
$24.3M 1.13%
+242,300
New +$22.6M
2016 Q3
0 quarters
DVA icon
25
DaVita
DVA
$10.1B
$23.1M 1.08%
350,000
-175,000
-33% -$12.3M
2013 Q4
11 quarters

Similar funds

Deerfield Management's Q3 2016 Portfolio in Review

As of Q3 2016, Deerfield Management held 116 positions worth $2.15B, down 15% from $2.54B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Deerfield Management withdrew a net $894M in Q3 2016, closing 26 positions and reducing 29 holdings. Its most notable exit was XenoPort, an estimated $81.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Deerfield Management opened a new position in Nevro worth $56M.

  • Deerfield Management's largest Q3 2016 buy was Nevro: 536,355 shares worth $56M.
  • Deerfield Management added most to Portola Pharmaceuticals in Q3 2016, an estimated $46.1M increase.
  • Deerfield Management's biggest Q3 2016 reduction was Horizon Therapeutics, cutting an estimated $143M.
  • Deerfield Management fully exited XenoPort in Q3 2016, selling an estimated $81.5M.
  • Deerfield Management's ten largest holdings make up 43% of its $2.15B portfolio in Q3 2016.
  • Deerfield Management opened 14 new positions and closed 26 in Q3 2016.
  • Deerfield Management's portfolio value fell 15% quarter-over-quarter to $2.15B.

Based on Deerfield Management's 13F filing for Q3 2016, filed 14 Nov 2016.